Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Black Diamond Therapeutics Inc (NQ: BDTX )

4.895 -0.005 (-0.10%)
Streaming Delayed Price Updated: 12:37 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 331,088
Open 4.920
Bid (Size) 4.880 (4)
Ask (Size) 4.910 (3)
Prev. Close 4.900
Today's Range 4.811 - 5.080
52wk Range 1.620 - 7.660
Shares Outstanding 36,213,654
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q1 2024
BDTX stock results show that Black Diamond Therapeutic beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire

Performance

YTD
+68.21%
+68.21%
1 Month
-2.49%
-2.49%
3 Month
+0.51%
+0.51%
6 Month
+117.56%
+117.56%
1 Year
+166.03%
+166.03%

More News

Read More
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutic: Q4 Earnings Insights
Via Benzinga
What 6 Analyst Ratings Have To Say About Black Diamond Therapeutic
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Black Diamond Therapeutics Announces Changes to Board of Directors
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Black Diamond Therapeutics Announces CEO Transition
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.